Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/43847
Título: In vitro synergistic interaction between DTA0100 and radiation in human cancercell lines
Autores/as: Bordón Rodríguez, Elisa de los Reyes 
León, Leticia G.
Ríos-Luci, Carla
Lara, Pedro C.
Padrón, José M.
Clasificación UNESCO: 32 Ciencias médicas
Palabras clave: Anticancer drugs
Antiproliferative
Cancer
Catalytic inhibitor
Cell lines, et al.
Fecha de publicación: 2012
Editor/a: 1871-5206
Publicación seriada: Anti-Cancer Agents in Medicinal Chemistry 
Resumen: DTA0100 is a new catalytic inhibitor of the human DNA topoisomerase IIα that induces G2/M phase cell cycle arrest in human solid tumor cells lines from various malignancies. In our study, we investigated the effectiveness of the combined treatment of ionizing radiation with DTA0100 on the survival of three representative human solid tumor cell lines: HeLa (cervix), WiDr (colon) and SW1573 (non-small cell lung cancer). The concomitant treatment of DTA0100 and irradiation showed a synergistic and antagonistic effect in the three cell lines tested. A synergistic cytotoxic effect of the combination of DTA0100 and radiation was confirmed by the median drug effect analysis method. It was found that in those protocols where the drug was administered after radiation the most synergistic effect was achieved. Our study constitutes the first in vitro evidence for synergistic effects between DTA0100 and radiation. This combination therapy might thus be expected to be more effective than either treatment alone in patients with cervical, colon and non-small cell lung cancer cells.
URI: http://hdl.handle.net/10553/43847
ISSN: 1871-5206
DOI: 10.2174/187152012802650057
Fuente: Anti-Cancer Agents in Medicinal Chemistry [ISSN 1871-5206], v. 12, p. 988-993
Colección:Artículos
Vista completa

Citas SCOPUSTM   

2
actualizado el 14-abr-2024

Visitas

48
actualizado el 22-jul-2023

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.